Scientist II, Cancer Genomics, Clinical Biomarker Development

Revolution Medicines•Redwood City, CA

1d•$132,000 - $166,000•Hybrid

About The Position

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: In this role you will join the Cancer Genomics group in Clinical Biomarker Development, which sits within the Translational Medicine department to develop biomarker, technology, and computational strategies for our RAS(ON) inhibitor programs. You will drive the application of advanced genomics analyses to maximize insight generation from clinical samples in our Phase I-III studies. This role offers the chance to work in a collaborative and innovative environment, including on cross-functional teams with other computational scientists, biomarker leads, biostatisticians, and preclinical scientists.

Requirements

A Ph.D. in Cancer Genomics, Genetics, Computational Biology, Bioinformatics, or similar degree.
A minimum of 2 - 6 years post-PhD experience analyzing cancer genomics data (post-doc, biotech, pharma, diagnostics, or combination).
A strong foundation in cancer biology, preferably with an understanding of RAS/MAPK signaling pathways in pancreatic, lung, or colorectal cancer.
Proficiency programming in R and/or Python, and expert in clearly documenting work with a version control system (git).
Experienced in Linux and the cloud, including HPC clusters and command line interface, and developing genomics workflows for large scale NGS datasets.
Experienced analyzing ctDNA or other liquid biopsy data derived from blood samples.
Experienced in the interrogation of DNA sequence data derived from tumor tissue, such as gene-panel, whole-exome or whole-genome data and downstream analytics (clonality estimates, copy number variation, chromosomal instability, mutational signatures, etc).
Practiced in commonly used tools and methods for DNA data analysis (GATK, Bioconductor, etc) and in utilizing publicly available datasets (TCGA, cBioPortal) to interrogate cancer genomics data.
Strong understanding of statistics and the ability to generate robust predictive models with multidimensional data.
Strong interpersonal, verbal and written communication skills; proactive, self-motivated, and adaptable in a dynamic environment.
Demonstrated ability to translate complex data into clear biological insight, and to influence project direction through data-driven scientific inquiry.

Nice To Haves

Experienced analyzing clinical endpoints (ORR, PFS, OS) including survival analysis.
Longitudinal ctDNA data analysis for predicting clinical endpoints (ORR, PFS, OS).
Deep knowledge of pancreatic, lung, or colorectal cancer, preferably including how progression, response and resistance may be mediated by biomarkers detected in tissue and/or blood biomarkers.

Responsibilities

Apply advanced analytics and genomics solutions to clinical biomarker data to inform research & development.
Integrate multi-omics datasets to interrogate disease biology and prognosis, mechanisms of resistance, and predict drug response.
Collaborate with cross functional teams, managing interactions with key stakeholders to deliver robust biomarker analyses and recommend follow up actions.
Communicate results to expert and non-expert audiences, including internal cross-functional team members and external collaborators, through scientific publications and presentations.